Biotechnology

ClinHope Officially Establishes Hong Kong Branch to Strengthen Asia-Pacific Market Presence

TAIPEI, Sept. 3, 2026 /PRNewswire/ -- ClinHope today announced the official establishment of its Hong Kong branch. Following its operations in Taiwan and the United States, this marks another step in expanding into the Asian market and deepening its global service footprint. As the biotech, phar...

2026-09-03 16:09 982

Everest Medicines Announces China NMPA Approval of CARDAMYST® for the Conversion of Acute Symptomatic Episodes of Paroxysmal Supraventricular Tachycardia (PSVT) to Sinus Rhythm in Adults

SHANGHAI, Sept. 3, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that China's National Medical Product...

2026-09-03 13:20 1091

The Galien Foundation Announces the Nominees for the Inaugural 2026 Prix Galien Korea Awards

Historic First Edition Launches in Partnership with MK Media (Maekyung), Yozma Group Korea, the Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KPBMA), and KoreaBIO at the World Knowledge Forum in Seoul SEOUL, South Korea, Sept. 3, 2026 /PRNewswire/ -- The Galien Foundation, the p...

2026-09-03 08:00 993

AAHRPP Accredits Five More Research Entities

21 more organizations earn reaccreditation WASHINGTON, Sept. 3, 2026 /PRNewswire/ -- The Association for the  Accreditation  of Human Research Protection Programs has awarded f...

2026-09-03 05:30 1034

EpiVax Launches AI-Enhanced Models for Immunogenicity Prediction

PROVIDENCE, R.I., Sept. 3, 2026 /PRNewswire/ -- EpiVax, Inc. is pleased to announce the release of AI-enabled enhancements toISPRI™ , its proprietary in sili...

2026-09-02 23:19 1193

NovaGo Therapeutics Closes USD 30 Million Series B Financing to Advance Proof-of-Concept Study in Acute Spinal Cord Injury

Round led by Neurimmune and Pureos, with participation from existing and new investors; complemented by non-dilutive funding from the Swiss Paraplegic Foundation and Wings for Life - Spinal Cord Research Foundation. SCHLIEREN, Switzerland, Sept. 2, 2026 /PRNewswire/ -- NovaGo Therapeutics AG, a ...

2026-09-02 18:00 2037

Texas Cardiac Arrhythmia Institute at St. David's Medical Center first in U.S. to participate in trial for innovative mapping and pulsed field ablation system

AUSTIN, Texas, Sept. 2, 2026 /PRNewswire/ -- The Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center recently became the first facility in the nation to participate in a clinical trial to evaluate the safety and effectiveness of a next-generation mapping and pulsed field ablat...

2026-09-02 09:37 1722

Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway

* The Phase 3 BiPASS™ study of Illuccix® and Gozellix® for prostate cancer imaging in the pre-biopsy setting has completed enrollment of 350 patients. * Telix has positively engaged with the FDA on a New Drug Application (NDA) pathway in the U.S. that would support new product reimbursement an...

2026-09-02 09:27 1105

Haier Biomedical Highlights Automated Biostorage and Connected Pharma Solutions at ISPE Singapore 2026

Haier Biomedical Accelerates Its Transformation into an Intelligent Biopharmaceutical Infrastructure Platform at ISPE Singapore 2026 SINGAPORE, Sept. 1, 2026 /PRNewswire/ -- Haier Biomedical  (SHA: 688139) showcased a portfolio of automated and digital solutions sp...

2026-09-01 22:50 2589

QC Ware and IonQ Demonstrate High-Precision Hybrid Quantum Workflow for Drug Discovery

Joint test on IonQ Forte hardware lands within 4% of benchmark, clearing the chemical-accuracy bar for enzyme active-site modeling via Amazon Braket PALO ALTO, Calif., Sept. 1, 2026 /PRNewswire/ -- QC Ware today announced a technology demonstration of a hybrid quantum-classical chemistry workflow...

2026-09-01 20:00 1751

Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy

Paxalisib Monotherapy Significantly Reduced Tumor Burden in Pre-Clinical Model of MSS/pMMR Colorectal Cancer, With the Addition of Pembrolizumab Driving a Further Reduction Paxalisib Was Well Tolerated as Monotherapy and in Combination with Checkpoint Inhibition Kazia is Preparing to Advance Pa...

2026-09-01 19:30 1356

Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer

Preclinical Data Show Paxalisib Combined With Standard-of-Care Therapy Is Well Tolerated and Produces Statistically Significant Antitumor Activity Three-Arm Expansion of the Ongoing TNBC Trial Will Evaluate Paxalisib Plus Fulvestrant, With Palbociclib, Versus Standard-of-Care First Patient Expec...

2026-09-01 19:15 1720

OncoC4 Appoints Dr. Steve Chen, JD, PhD as General Counsel

ROCKVILLE, Md., Sept. 1, 2026 /PRNewswire/ -- OncoC4, Inc., a late clinical-stage biopharmaceutical company developing novel medicines for cancer and neurodegenerative diseases, today announced the appointment of Steve Chen, JD, PhD, as General Counsel. Dr. Chen brings nearly two decades of lega...

2026-09-01 19:00 1720

JIANGXI BIO Announced 2026 Interim Results

Overseas Contract Orders Reach Nearly RMB27.4 mn and R&D Translation Gains Momentum, with the AEPC Platform Reshaping the R&D Paradigm for Equine Polyclonal Antibody Interim Results Highlights   Key Financial Indicators * Revenue amounted to RMB83.3 mn; gross profit amounted to RMB60.3 mn, ...

2026-09-01 14:44 3885

Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering

Company to host a corporate update call Tuesday, September 1st at 8:00am ET SYDNEY, Sept. 1, 2026 /PRNewswire/ -- Kazia Therapeutics Limited  (NASDAQ: KZIA) ("Kaz...

2026-09-01 07:23 3342

CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum

CS2009 Achieved Key Clinical Validations for Efficacy and Safety As of August 2026, updated data further confirmed the favorable safety profile of CS2009 and demonstrated strengthened efficacy across multiple key cohorts compared with the data presented at ASCO in May 2026. With expanded patient...

2026-08-31 20:38 2796

SIBIONICS Showcases GS3 in Melbourne, Advancing More Efficient, AI-Powered Glucose Monitoring

MELBOURNE, Australia, Aug. 31, 2026 /PRNewswire/ -- SIBIONICS showcased its sensor innovation and AI-powered glucose monitoring at the joint IDF-WPR, ADC and Metabolic Diseases 2026 congress, held in Melbourne from 18–21 August. Through Booth #1, a scientific symposium and on-site interviews with...

2026-08-31 12:17 786

Chula Researchers Develop Synthetic Boar Scent Mimicking Natural Pheromones to Reduce Disease Outbreak Risks in Pig Farms

BANGKOK, Aug. 31, 2026 /PRNewswire/ -- Researchers from Chulalongkorn University 's Faculty of Veterinary Science have developed synthetic boar scent mimicking natural pheromones , providing a safer way to stimulate repro...

2026-08-31 10:00 865

Amai Proteins' sweelin® Approved for Sale in Israel, Opening the Market to a New Generation of Reduced-Sugar Food and Beverage Products

Third regulatory approval in less than six months enables food and beverage manufacturers to commercialize products sweetened with sweelin® in Israel. REHOVOT, Israel, Aug. 31, 2026 /PRNewswire/ -- Amai Proteins announces that the Israeli Ministry of Health has officially approvedsweelin® as a no...

2026-08-31 09:00 1222

Subsidised Access to Columvi® Now Available for Eligible Patients with Relapsed or Refractory DLBCL in Singapore

* Columvi (glofitamab) will be added to the Cancer Drug List (CDL) and Medication Assistance Fund (MAF) on 1 September 2026 for eligible patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for autologous stem cell transplant and have received at lea...

2026-08-31 09:00 1810
12345 ... 184